Eliem Therapeutics (NASDAQ:ELYM) Trading Up 0.5%

Eliem Therapeutics, Inc. (NASDAQ:ELYM) traded up 0.5% during mid-day trading on Monday . The stock traded as high as $4.12 and last traded at $3.87. 95,362 shares changed hands during trading, a decline of 84% from the average session volume of 583,013 shares. The stock had previously closed at $3.85.

Eliem Therapeutics Stock Down 2.4 %

The stock has a market cap of $101.46 million, a price-to-earnings ratio of -2.49 and a beta of 0.51. The business’s 50 day simple moving average is $3.02 and its 200 day simple moving average is $2.79.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Eliem Therapeutics stock. BML Capital Management LLC lifted its holdings in Eliem Therapeutics, Inc. (NASDAQ:ELYM) by 0.6% during the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,193,742 shares of the company’s stock after acquiring an additional 13,742 shares during the period. Eliem Therapeutics makes up approximately 4.0% of BML Capital Management LLC’s investment portfolio, making the stock its 7th largest position. BML Capital Management LLC owned about 7.91% of Eliem Therapeutics worth $6,011,000 at the end of the most recent quarter. 69.76% of the stock is owned by institutional investors.

Eliem Therapeutics Company Profile

Eliem Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy, and other disorders of the peripheral and central nervous systems. Its lead drug candidate is ETX-123, a Kv7.2/3 potassium channel opener, which is in preclinical for the treatment of neuronal excitability disorders, such as epilepsy, pain, depression, and others; and ETX-155 for the treatment of major depressive disorder and focal onset seizures that is in Phase 2a clinical trial.